All Relations between cannabis and cannabinoids

Publication Sentence Publish Date Extraction Date Species
Sunil K Aggarwal, Gregory T Carter, Mark D Sullivan, Craig ZumBrunnen, Richard Morrill, Jonathan D Maye. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. Journal of opioid management. vol 5. issue 3. 2009-08-26. PMID:19662925. cannabis contains more than 100 different cannabinoids and has the capacity for analgesia through neuromodulation in ascending and descending pain pathways, neuroprotection, and anti-inflammatory mechanisms. 2009-08-26 2023-08-12 Not clear
C A Vercelli, J Aisemberg, S Billi, M Cervini, M L Ribeiro, M Farina, A M Franch. Anandamide regulates lipopolysaccharide-induced nitric oxide synthesis and tissue damage in the murine uterus. Reproductive biomedicine online. vol 18. issue 6. 2009-08-18. PMID:19490788. anandamide, a major endocannabinoid, mimics some of the psychotropic, hypnotic and analgesic effects of delta(9)-tetrahydrocannabinol, the psychoactive component of marijuana. 2009-08-18 2023-08-12 Not clear
Ahmed M Galal, Desmond Slade, Waseem Gul, Abir T El-Alfy, Daneel Ferreira, Mahmoud A Elsohl. Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. Recent patents on CNS drug discovery. vol 4. issue 2. 2009-08-18. PMID:19519560. naturally occurring cannabinoids (phytocannabinoids) are biosynthetically related terpenophenolic compounds uniquely produced by the highly variable plant, cannabis sativa l. natural and synthetic cannabinoids have been extensively studied since the discovery that the psychotropic effects of cannabis are mainly due to delta(9)-thc. 2009-08-18 2023-08-12 Not clear
Ahmed M Galal, Desmond Slade, Waseem Gul, Abir T El-Alfy, Daneel Ferreira, Mahmoud A Elsohl. Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. Recent patents on CNS drug discovery. vol 4. issue 2. 2009-08-18. PMID:19519560. this article reviews patents (2003-2007) that describe methods for isolation of cannabinoids from cannabis, chemical and chromatographic methods for their purification, synthesis, and potential therapeutic applications of these compounds. 2009-08-18 2023-08-12 Not clear
Mohini Ranganathan, Gabriel Braley, Brian Pittman, Thomas Cooper, Edward Perry, John Krystal, Deepak Cyril D'Souz. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology. vol 203. issue 4. 2009-08-17. PMID:19083209. cannabis is one of the most widely used illicit substances, and there is growing interest in the therapeutic applications of cannabinoids. 2009-08-17 2023-08-12 Not clear
Mohini Ranganathan, Gabriel Braley, Brian Pittman, Thomas Cooper, Edward Perry, John Krystal, Deepak Cyril D'Souz. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology. vol 203. issue 4. 2009-08-17. PMID:19083209. furthermore, the existing literature on the neuroendocrine effects of cannabinoids is limited by small sample sizes (n = 6-22), heterogeneous samples with regard to cannabis exposure (lumping users and nonusers), lack of controlling for chronic cannabis exposure, differing methodologies, and limited dose-response data. 2009-08-17 2023-08-12 Not clear
William Marrs, Nephi Stell. Measuring endocannabinoid hydrolysis: refining our tools and understanding. The AAPS journal. vol 11. issue 2. 2009-08-12. PMID:19424807. endocannabinoids (ecbs) are lipid transmitters that are released from membrane precursors in response to specific stimuli, activate cannabinoid receptors--the molecular targets of compounds produced by cannabis sativa--and are then rapidly inactivated by uptake and enzymatic hydrolysis. 2009-08-12 2023-08-12 Not clear
Joel E Schlosburg, Brittany L A Carlson, Divya Ramesh, Rehab A Abdullah, Jonathan Z Long, Benjamin F Cravatt, Aron H Lichtma. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. The AAPS journal. vol 11. issue 2. 2009-08-12. PMID:19430909. the only treatment currently shown consistently to alleviate cannabinoid withdrawal in both animals and humans is substitution therapy using the psychoactive constituent of marijuana, delta(9)-tetrahydrocannabinol (thc). 2009-08-12 2023-08-12 mouse
Joel E Schlosburg, Brittany L A Carlson, Divya Ramesh, Rehab A Abdullah, Jonathan Z Long, Benjamin F Cravatt, Aron H Lichtma. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. The AAPS journal. vol 11. issue 2. 2009-08-12. PMID:19430909. these results support the concept of targeting endocannabinoid metabolizing enzymes as a promising treatment for cannabis withdrawal. 2009-08-12 2023-08-12 mouse
Alan J Budney, Joshua A Lil. Moving beyond the cannabis controversy into the world of the cannabinoids. International review of psychiatry (Abingdon, England). vol 21. issue 2. 2009-08-04. PMID:19367502. moving beyond the cannabis controversy into the world of the cannabinoids. 2009-08-04 2023-08-12 Not clear
Ziva D Cooper, Margaret Hane. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. International review of psychiatry (Abingdon, England). vol 21. issue 2. 2009-08-04. PMID:19367504. the rewarding and positive reinforcing effects of the primary psychoactive component of smoked cannabis, delta-9-tetrahydrocannabinol (thc) are mediated by the cannabinoid cb1 receptor. 2009-08-04 2023-08-12 Not clear
Ziva D Cooper, Margaret Hane. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. International review of psychiatry (Abingdon, England). vol 21. issue 2. 2009-08-04. PMID:19367504. this paper will review findings implicating the cb1 receptor in the behavioural effects of exogenous cannabinoids with a focus on cannabinoid dependence and reinforcement, factors that contribute to the maintenance of chronic cannabis smoking despite negative consequences. 2009-08-04 2023-08-12 Not clear
Kathryn A Seely, Mark S Levi, Paul L Prathe. The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists. The Journal of pharmacology and experimental therapeutics. vol 330. issue 1. 2009-07-27. PMID:19359525. it is interesting that cannabinoids, derived from the marijuana plant (cannabis sativa), produce similar protective effects via cb1 and cb2 receptors. 2009-07-27 2023-08-12 mouse
Antonio Waldo Zuard. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 30. issue 3. 2009-07-23. PMID:18833429. cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. 2009-07-23 2023-08-12 Not clear
Sumner H Burstein, Robert B Zurie. Cannabinoids, endocannabinoids, and related analogs in inflammation. The AAPS journal. vol 11. issue 1. 2009-07-23. PMID:19199042. this review covers reports published in the last 5 years on the anti-inflammatory activities of all classes of cannabinoids, including phytocannabinoids such as tetrahydrocannabinol and cannabidiol, synthetic analogs such as ajulemic acid and nabilone, the endogenous cannabinoids anandamide and related compounds, namely, the elmiric acids, and finally, noncannabinoid components of cannabis that show anti-inflammatory action. 2009-07-23 2023-08-12 Not clear
Ester Fride, Datta Ponde, Aviva Breuer, Lumir Hanu. Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors. Neuropharmacology. vol 48. issue 8. 2009-07-17. PMID:15910887. delta-9 tetrahydrocannabinol (delta(9)-thc) and (-)-cannabidiol ((-)-cbd) are major constituents of the cannabis sativa plant with different pharmacological profiles: (delta(9)-thc activates cannabinoid cb(1) and cb(2) receptors and induces psychoactive and peripheral effects. 2009-07-17 2023-08-12 mouse
Roger G Pertwee, Adèle Thomas, Lesley A Stevenson, Yehoshua Maor, Raphael Mechoula. Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. Neuropharmacology. vol 48. issue 8. 2009-07-17. PMID:15910889. previous experiments showed that r-(+)-win55212-induced inhibition of electrically-evoked contractions of mouse vasa deferentia could be antagonized by cannabidiol in a manner that appeared to be competitive but not to involve direct competition for established cannabinoid receptors. 2009-07-17 2023-08-12 mouse
Mauro Maccarron. Endocannabinoids and reproductive endocrinology. Current opinion in investigational drugs (London, England : 2000). vol 10. issue 4. 2009-07-14. PMID:19337950. the endocannabinoids anandamide and 2-arachidonoylglycerol mimic delta9-tetrahydrocannabinol, the chemical component responsible for the psychoactive properties of cannabis sativa, by binding to both type 1 and type 2 cannabinoid receptors. 2009-07-14 2023-08-12 human
Barbara Budzyńska, Marta Kruk, Grazyna Biał. Effects of the cannabinoid CB1 receptor antagonist AM 251 on the reinstatement of nicotine-conditioned place preference by drug priming in rats. Pharmacological reports : PR. vol 61. issue 2. 2009-07-14. PMID:19443943. tobacco and cannabis are among the most widely abused drugs in humans, and recently, the functional interaction between nicotine and cannabinoids has been reported. 2009-07-14 2023-08-12 rat
Saoirse E O'Sullivan, Yan Sun, Andrew J Bennett, Michael D Randall, David A Kendal. Time-dependent vascular actions of cannabidiol in the rat aorta. European journal of pharmacology. vol 612. issue 1-3. 2009-07-09. PMID:19285060. the vascular effects of cannabidiol were not affected by endothelial denudation, nitric oxide synthase inhibition, pertussis toxin, cannabinoid cb1 or cannabinoid cb2 receptor antagonism, or capsaicin pre-treatment. 2009-07-09 2023-08-12 rat